Hormonal and subjective responses to intravenous meta- chlorophenylpiperazine in bulimia nervosa

Archives of General Psychiatry

Volumn 54, Issue 6, 1997, Pages 521-527

  Levitan, Robert D ^a,c   Kaplan, Allan S ^a   Joffe, Russell T ^b,d   Levitt, Anthony J ^b   Brown, Gregory M ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PLACEBO; PROLACTIN; SEROTONIN AGONIST; SODIUM CHLORIDE;

ADULT; ANXIETY; ARTICLE; BULIMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SEROTONINERGIC SYSTEM;

EID: 0031007656     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830180027004     Document Type: Article

References (77)

1. Goudie A, Thornton E, Wheeler T. Effects of Lilly 110 140, a specific inhibitor of 5-hydroxytryptamine uptake, on food intake and on 5-hydroxytryptophan-induced anorexia: evidence for serotonergic inhibition of feeding. J Pharm Pharmacol. 1976;28:318-320.
2. Blundell JE. Is there a role for serotonin in feeding? Int J Obesity. 1977;1:15-42.
3. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotonergic transmission diminish selective carbohydrate consumption by rats. Life Sci. 1979;24:895-904.
4. Blundell J. Serotonin and appetite. Neuropharmacology. 1984;23:1537-1551.
5. Leibowitz S, Shor-Posner G. Brain serotonin and eating behavior. Appetite. 1986;7:1-14.
6. Meltzer HY, Aurora RC, Baber R, Tricou BJ. Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry. 1981;38:1322-1326.
7. DeMeyer MK, Shea PA, Hendrie HC, Yoshimura NN. Plasma tryptophan and five other amino acids in depressed and normal subjects. Arch Gen Psychiatry. 1981;38:642-646.
8. Moller SE, Kirk L, Brandrup E, Ortmann J, Elley J. Plasma tryptophan in depression. Biol Psychiatry. 1983;10:30-46.
9. Heninger GR, Charney DS, Sternberg DE. Serotonergic function in depression. Arch Gen Psychiatry. 1984;41:398-402.
10. Briley M. Imipramine binding: its relationship with serotonin. In: Green AR, ed. Neuropharmacology of Serotonin. New York, NY: Oxford University Press Inc; 1985:50-78.
11. Young SN, Smith SE, Pihl R, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl). 1985;87:173-177.
12. Koyama T, Meltzer HY. A biochemical and neuroendocrine study of the serotonergic system in depression. In: Hippius H, Klerman GL, Matussek N, eds. New Results in Depression Research. New York, NY: Springer-Verlag NY Inc; 1986:169-188.
13. Cowen PJ, Charig EM. Neuroendocrine responses to intravenous tryptophan in major depression. Arch Gen Psychiatry. 1987;44:958-966.
14. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47:411-418.
15. Price LH, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects. Am J Psychiatry. 1991; 148:1515-1525.
16. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion: enhanced sensitivity in young men at genetic risk for major affective disorders. Arch Gen Psychiatry. 1994;51:687-697.
17. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946-951.
18. Glennon R. Central serotonin receptors as targets for drug research. J Med Chem. 1987;30:1-12.
19. Kahn RS, Wetzler S, van Praag HM, Asnls GM, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res. 1988;25:101-104.
20. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Hypotheses relating serotonergic dysfunction to the etiology and treatment of panic and generalized anxiety disorders. In: Coccaro EF, Murphy DL, eds. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1990:71-97.
21. Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry. 1992;32:457-461.
22. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res. 1991;38:227-236.
23. Valzelli L. Aggressive behavior induced by isolation. In: Garattini S, Sigg E, eds. Excerpta Medica. Belle Meade, NJ: Excerpta Medica-Princeton; 1969:70-76.
24. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry. 1976;33:1193-1197.
25. Brown GL, Ballenger JC, Minchiello MD, Goodwin FK. Human aggression and its relationship to cerebrospinal fluid 5-hydroxyindolacetic acid, 3-methoxy-4-hydroxyphenolglycol and homovanillic acid. In: Sandler M, ed. Psychopharmacology of Aggression. New York, NY: Raven Press; 1979:131-148.
26. Ballenger JC, Goodwin FK, Major LF, Brown GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979;36:224-227.
27. Kantak K, Hegstrand L, Eichelman B. Facilitation of shock-induced fighting following intraventricular 5,7-dihydroxytryptamine and 6-hydroxy DOPA. Psychopharmacololgy (Berl). 1981;74:157-160.
28. Brown GL, Ebert MH, Goyer PF, Jimerson D, Klein WJ, Bunney WE, Goodwin FK. Aggression, suicide and serotonin: relationship to CSF amine metabolites. Am J Psychiatry. 1982;139:741-746.
29. Linnoila M, Virkunnen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxy-indolacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983;33:2609-2614.
30. Molina V, Gobaille S, Mandel P. Effects of serotonin-mimetic drugs on mouse-killing behavior. Aggressive Behav. 1986;12:201-211.
31. Soubrie P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci. 1986;9:319-364.
32. Virkkunen M, Nuutila A, Goodwin FK, Linnoila M. Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry. 1987;44:241-247.
33. Hollander E, Stein DJ, Decaria CM, Cohen L, Saoud JB, Skodol AE, Kellman D, Rosnick L, Oldham JM. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry. 1994;151:277-280.
34. Hatsukami D, Eckert E, Mitchell J, Pyle RL. Affective disorders and substance abuse in women with bulimia. Psychol Med. 1984;14:701-704.
35. Mitchell J, Hatsukami D, Eckert E, Pyle RL. Characteristics of 275 patients with bulimia. Am J Psychiatry. 1985;142:482-485.
36. Laessle R, Wittchen H, Fichter M, Pirke KM. The significance of subgroups of bulimia and anorexia nervosa: lifetime frequency of psychiatric disorders. Int J Eat Disord. 1989;8:569-574.
37. Kaye WH, Ebert MH, Gwirtsman HE, Weiss SR. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am J Psychiatry. 1984;141:1598-1601.
38. Kaye WH, Ballenger JC, Lydiard RB, Stuart GW, Laraia RN, O'Neil P, Fossey MD, Stevens V, Lesser S, Hsu G. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990;147:225-229.
39. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry. 1992;49:132-138.
40. Goldbloom DS, Hicks L, Garfinkel PE. Platelet serotonin uptake in bulimia nervosa. Biol Psychiatry. 1990;28:644-647.
41. Marazziti D, Macchi E, Rotondo A, Placidi GF, Cassano GB. Involvement of the serotonin system in bulimia. Life Sci. 1988;43:2123-2126.
42. Lydiard RB, Brady KT, O'Neil PM, Schleisier-Carter B, Hamilton S, Rogers Q, Ballenger GC. Precursor amino acid concentrations in normal weight bulimics and normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:893-898.
43. Kayef WH, Gwirtsman HE, Brewerton TD, George DT, Wurtman RJ. Bingeing behavior and plasma amino acids: a possible involvement of brain serotonin in bulimia nervosa. Psychiatry Res. 1988;23:31-43.
44. Goldbloom DS, Garfinkel PE, Katz R, Brown G. The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa. Psychosom Med. 1990; 52:225-226.
45. Jimerson DC, Wolfe BE, Metzger ED, Levine JM. Serotonin function in bulimia nervosa. Presented at the 147th Annual Meeting of the American Psychiatric Association; May 26, 1994; Philadelphia, Pa.
46. Brewerton TO, Mueller E, Lesem MD, Brandt HA, Quearry B, George DT, Murphy DL, Jimerson DC. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Arch Gen Psychiatry. 1992;49:852-861.
47. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry. 1991;30:1139-1166.
48. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology (Berl). 1990;100:339-344.
49. Walsh BT, Lo ES, Cooper T, Lindy DC, Roose SP, Gladis M, Glassman AH. Dexamethasone suppression test and plasma dexamethasone levels in bulimia. Arch Gen Psychiatry. 1987;44:797-803.
50. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonergic agonist, in humans. J Clin Endocrinol Metab. 1985;61:1179-1184.
51. Hamik A, Petrouka SJ. 1-(m-chlorophenylpiperazine) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989;25:569-575.
52. Hoyer D. Functional correlates of serotonin 5-HT-1 recognition sites. J Recept Signal Transduct Res. 1988;8:59-81.
53. Mueller EA, Murphy DL, Sunderland T. Further studies of the putative serotonin agonist m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl). 1986;89:388-391.
54. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiological effects of m-chlorophenylpiperazine given intravenously to healthy volunteers. Psychopharmacology (Berl). 1989;98:275-282.
55. Kalus O, Wetzler S, Kahn RS, Asnis GM, van Praag HM. A dose-response study of m-chlorophenylpiperazine in normal subjects. Psychopharmacology (Berl). 1992;106:388-390.
56. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
57. Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-III. New York: New York State Psychiatric Institute, Biometrics Research; 1982.
58. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
59. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;6:278-296.
60. Johnson C. Initial consultation for patients with bulimia and anorexia nervosa. In: Garner DM, Garfinkel PE, eds. Handbook of Psychotherapy for Anorexia Nervosa and Bulimia. New York, NY: Guilford Press; 1985:34-49.
61. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-CPP in patients and healthy subjects. Arch Gen Psychiatry. 1988;45:177-185.
62. Bagdy G, Calogero AE, Murphy DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology. 1989;125:2664-2669.
63. Levy AB, Dixon KN, Malarkey WB. Pituitary response to TRH in bulimia. Biol Psychiatry. 1988;23:476-484.
64. Gil-Ad I, Zambotti F, Carruba MO, Vicentini L, Muller EE. Stimulatory role for brain serotonergic system on prolactin secretion in male rat. Proc Soc Exp Biol Med. 1976;151:512-518.
65. Advis JP, Simpkins JW, Bennett J, Meites J. Serotonergic control of prolactin release in male rats. Life Sci. 1979;24:359-366.
66. Schettini G, Quattrone A, Di Renzo G, Preziosi P. Serotonergic involvement in neuroendocrine function. Pharmacol Res. 1980;12:249-254.
67. Willoughby JO, Menadue M, Jervois P. Function of serotonin in physiological secretion of growth hormone and prolactin: action of 5,7-dihydroxytryptamine, fenfluramine and p-chlorophenylalanine. Brain Res. 1982;249:291-299.
68. Kaplan AS, Garfinkel PE, Brown GM. The DST and TRH test in bulimia nervosa. Br J Psychiatry. 1989;154:86-92.
69. deGroot J, Rodin G, Olmstead M. Alexithymia, depression and treatment outcome in bulimia nervosa. Comp Psychiatry. 1995;36:1-9.
70. Goodwin GM, Fairburn CG, Cowen PJ. The effects of dieting and weight loss on neuroendocrine responses to tryptophan, clonidine, and apomorphine in volunteers: important implications for neuroendocrine investigations in depression. Arch Gen Psychiatry. 1987;44:952-957.
71. Brewerton TD, Brandt HA, Lesem MD, Murphy DL, Jimerson DC. Serotonin in eating disorders. In: Coccaro EF, Murphy DL, eds. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1990:153-184.
72. Azmitia EC, McEwen BE. Adrenal-cortical influence on rat brain tryptophan hydroxylase activity. Brain Res. 1974;78:291-302.
73. Rittenhouse PA, Levy AD, Bethea CL, Van de Kar LD. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c/2 receptors. Endocrinology. 1993;133:661-667.
74. Leibowitz S, Weiss G, Suh J. Medial hypothalamic nuclei mediate serotonin's inhibitory effect on feeding behavior. Pharmacol Biochem Behav. 1990;37:735-742.
75. Kennett GA, Curzon G. Evidence that mCPP may have behavioral effects mediated by central 5-HT1c receptors. Br J Pharmacol. 1988;94:137-147.
76. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1c receptors mediate 1-3 (chlorophenyl) piperazine-induced hypophagia. Br J Pharmacol. 1991;103:2016-2020.
77. Dourish C, Clark M, Fletcher A, Iversen S. Evidence that blockade of post-synaptic 5-HT-1 receptors elicits feeding in satiated rats. Psychopharmacology (Berl). 1989;97:54-58.